We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

GloResponse™ NF-κB-RE-luc2P HEK293 Cell Line

GloResponse™ NF-κB-RE-luc2P HEK293 cells response to TNF-α titration.

Luciferase Reporter Cell Line with NF-κB Response Element

  • Rapid, bioluminescent detection of any cellular response resulting in modulation of NF-κB activities

Size

Catalog number selected: E8520

$ 11,638.00 Your price: Log in

GloResponse™ NF-κB-RE-luc2P HEK293 Cell Line
2 vials
$ 11,638.00
Your price: Log in

The GloResponse™ NF-κB-RE-luc2P HEK293 Cell Line is a clonal derivative of Human Embryonic Kidney 293 (HEK293) cells. These cells contain a luciferase gene (luc2P) under the control of a minimal TATA promoter with multiple Nuclear Factor-κB response elements (NF-κB-REs). NF-κB-REs are the DNA-binding sequences for the NF-κB transcription factor, which is responsible for regulating inflammation, immune response, cell growth and apoptosis. The GloResponse™ NF-κB-RE-luc2P HEK293 Cell Line is designed for rapid and convenient analysis of any cellular response that results in modulation of NF-κB activities.

The GloResponse™ Cell Lines incorporate the improvements developed for the pGL4 family of reporter vectors for enhanced performance. The destabilized luc2P luciferase reporter is used for improved responsiveness to transcriptional dynamics. The luc2P gene is codon optimized for enhanced expression in mammalian cells, and the pGL4 plasmid backbone was engineered to reduce background reporter expression. The result is a cell line with very high induction levels when the pathway of interest is activated.

GloResponse NF-KB-RE-luc2P HEK293 cells response to TNF-alpha titration.

GloResponse™ NF-κB-RE-luc2P HEK293 cells response to TNF-α titration. A total of 10,000 GloResponse™ NF-κB-RE-luc2P HEK293 cells per well were dispensed into each well of a 384-well plate, and twofold serial dilutions of TNF-α were added to induce reporter gene expression. After 5 hours of induction in a tissue culture incubator, luciferase activity was quantified using the ONE-Glo™ Luciferase Assay System Reagent on the Berthold® LB 96 V Luminometer. n = 8 for each data point.

Specifications

What's in the box?

Item Part # Size

NF-κB-luc2P HEK293 Cell Line

E852A 2 × 1 vial

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

XX

Patents and Disclaimers

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE LABEL LICENSE. If the researcher is not willing to accept the terms of this label license, and the product is unused, Promega will accept return of the unused product and provide the researcher with a full refund.
Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for money or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, researchers must either: (1) use luminescent assay reagents purchased from Promega for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA. This label license relates to Promega patents and/or patent applications on improvements to the luciferase gene.

Patent Pending.

U.S. Pat. No. 8,008,006 and European Pat. No. 1341808.

Commercial use of this cell line requires a license from AdVec Inc.

Use of Genetically Modified Microorganisms (GMM)
Information for European Customers: These products are genetically modified as described in Promega technical literature. As a condition of sale, use of this product must be in accordance with all applicable local guidelines on the contained use of genetically modified microorganisms, including the Directive 2009/41/EC of the European Parliament and of the Council.

HEK293 cells were obtained under license from AdVec Inc.

workflow-background
Choose your country

Americas

Brazil
Canada
United States

Pacific Asia

Australia
India
Japan
Korea, Republic of
Singapore

Europe

Austria
Belgium
Denmark
Estonia
Finland
France
Germany
Iceland
Italy
Luxembourg
Netherlands
Norway
Poland
Spain
Sweden
Switzerland
United Kingdom